Dexcom

Dexcom controls a CGM sensor manufacturing and regulatory moat: electrochemical biosensor fabrication at scale with FDA iCGM classification. The bottleneck is the combination of (1) enzyme-coated electrode manufacturing yield at millions of units/month, (2) FDA-cleared wear-time extension (10→15→15.5 days), and (3) the CONNECT RCT unlocking the ~30M Type 2 non-insulin TAM. Switching costs are clinical workflow + patient habit formation + payer contract integration, not just sensor hardware.

• Manufacturing: 3 facilities — Mesa, AZ (primary); Penang, Malaysia; Athenry, Ireland (building out). FDA warning letter (March 2025) for Mesa/San Diego non-conformities in manufacturing processes and quality systems — a resolved risk but demonstrates the regulatory barrier to entry for new competitors.
• iCGM classification: FDA Class II 510(k) clearance for G7 as an integrated CGM (iCGM) — enables insulin-dosing decisions without fingerstick confirmation, a higher bar than basic glucose monitoring.
• Wear-time progression: G7 (10-day, 2023) → G7 15 Day (late 2025) → 15.5-day sensor authorized Canada (July 2026). Each extension requires new FDA clearance with clinical accuracy data. Abbott Libre 3 is at 15 days; Dexcom now matches or exceeds.
• Stelo OTC: First FDA-cleared over-the-counter glucose biosensor (August 2024) — opens non-prescription channel for prediabetes and Type 2 non-insulin users. No competitor has an FDA-cleared OTC CGM.

The moat is the installed-base + sensor-replacement flywheel, plus FDA-cleared product development, payer/channel relationships, and manufacturing know-how. CGM is not a commodity sensor market; replacement friction, reimbursement, and user habit formation create recurring stickiness.

The moat is the installed base plus replacement cadence, regulatory clearance, channel access, and manufacturing/quality execution. Switching costs are behavioral and clinical, not just contractual.

Dexcom's CGM moat is narrowing on TWO fronts since the 08-02 note. The 08-02 note framed the moat as "iCGM classification + OTC first-mover + 15-day wear + enzyme-electrode manufacturing yield." Two Abbott moves since then attack that moat from different directions: (1) Libre Duo adds a whole sensing dimension (continuous ketone) Dexcom does not have, and (2) Google Health is commoditizing the software/AI interpretation layer that Dexcom was counting on owning.

1. Abbott Libre Duo 10 Day — FDA De Novo authorization (2026-08-25). World's first dual glucose-ketone sensing technology. First system to meet the FDA's iCGM standard and the new iCGK (integrated continuous glucose-and-ketone monitoring) standard — a new regulatory benchmark Dexcom has no product to meet. Breakthrough device designation; CE Mark May 27, 2026; US launch "later in 2026." Source: Abbott PR, prnewswire.com 302859742 (2026-08-25); mddionline.com (2026-08-26).
2. Abbott + Google Health partnership (2026-08-11). Multi-year collaboration: Lingo glucose data flows into the Google Health app, interpreted by a Gemini-powered "Google Health Coach" for nutrition/activity/sleep guidance, plus "one of the largest real-world metabolic health studies to date." Source: abbott.mediaroom.com (2026-08-11); blog.google (2026-08-11).
3. Dexcom Stelo pediatric expansion (2026-06-12, for completeness). FDA expanded Stelo OTC clearance to ages 2+ (non-insulin) — a Dexcom STRENGTHENING catalyst the 08-02 note did not capture (it only cites the 2024 adult clearance). Source: Medscape.

The DB row carried toll_road_tier=DIRECT_BOTTLENECK but toll_road_score=NULL and all three sub-scores NULL — a tier/score contradiction. Re-scored against the three-question test:

Composite = 6 → STRONG PROXY (downgrade from the stale DIRECT_BOTTLENECK tier). A DIRECT_BOTTLENECK (8–9) requires a near-non-bypassable toll; a duopoly where the #2 is out-innovating on a new sensing dimension and Big Tech owns the interpretation layer is a strong proxy, not a direct toll.

The Libre Duo iCGK clearance opens a clinical segment Dexcom cannot currently serve — DKA-risk monitoring:

• US Type 1 diabetes population ≈ 1.6M adults (CDC). DKA is a leading cause of preventable hospitalization/death in T1D, and ketone monitoring is the early-warning signal.
• SGLT2-inhibitor users ≈ 7M+ US adults (empagliflozin/dapagliflozin/canagliflozin, prescribed for diabetes + HF + CKD) carry a documented euglycemic DKA risk — ketone sensing is the monitoring answer.
• Dexcom has zero announced ketone-sensing product. A competitor must run its own De Novo/iCGK clearance; the fastest credible path is 18–24 months behind Abbott's Aug-2026 authorization.
• Switching cost inverts here: a T1 insulin-pump or SGLT2 patient who wants DKA alerts must move to Abbott, and once on Libre Duo + a pump, the habit/ecosystem lock now favors Abbott. The ketone gap is a pull-through threat to Dexcom's core T1 insulin base, not just an adjacent market.

• Abbott Lingo samples glucose every 1 minute vs. Dexcom Stelo every 15 minutes — a data-frequency advantage in the wellness segment where "did this meal spike me?" is the use case.
• The Google Health Coach (Gemini) becomes the default interpretation layer for Lingo data. The CGM moat was "hardware + software + data"; Google commoditizes the software/data-interpretation leg, leaving Dexcom's moat as hardware + regulatory + manufacturing only.
• OTC is not insurance-reimbursed, so the wellness segment is won on consumer software experience — exactly where a hyperscaler's AI/UX is the strongest substitute.

• product_service: Dexcom G7/G6/Stelo continuous glucose monitoring (CGM) systems.
• technical function: Subcutaneous enzyme-based electrochemical sensor measures interstitial glucose; wearable transmitter sends data to app/receiver; algorithm displays glucose values/trends/alerts. (same 10-K, Business)
• why it is hard: proprietary sensor chemistry/wire, biocompatibility, calibration algorithms, manufacturing scale, regulatory clearances, payer coverage, IP. (same 10-K, Business/Risk Factors)
• substitutes: fingerstick blood glucose meters, Abbott FreeStyle Libre, Medtronic CGM, lab A1c. (same 10-K, Competition/Risk Factors)
• pricing power: MED — reimbursed and sticky, but Abbott competition and payer pressure; Stelo OTC cash-pay lower. (same 10-K, Risk Factors)

DexCom sells CGM systems that measure glucose in interstitial fluid continuously, provide alerts, and transmit data to a smartphone, smartwatch, or receiver. The current-generation product is G7, which the 10-K describes as smaller, fully disposable, and cleared/launched in recent years.

Key product characteristics from the filing:

• G7 received FDA clearance and launched in the U.S. in 2023.
• It is smaller than prior generation G6.
• It uses a wearable sensor with transmitter and does not require routine fingerstick calibration.
• It sends readings via Bluetooth and supports remote data sharing through DexCom’s software ecosystem.
• Sensor wear is approximately 10 days, which creates a recurring consumable purchase cycle.

Source: DexCom FY2023 Form 10-K, Item 1/Item 7 discussion of G7 and product platforms, SEC accession 0001093557-24-000004, filed 2024-02-08, accessed 2026-04-26.

The primary direct competitor is Abbott’s FreeStyle Libre CGM platform. Abbott’s FY2023 10-K shows Abbott Diabetes Care segment revenue of $5,741M, which is larger than DexCom’s total company revenue of $3,622.3M. That is a direct contradiction to any thesis that DexCom is the largest revenue generator in CGM globally.

Source: Abbott Laboratories FY2023 Form 10-K, filed 2024-02-16, SEC EDGAR company filing index under CIK 0000001800, accessed 2026-04-26.

Other substitutes include traditional blood glucose meters and competing CGM systems from Medtronic and Senseonics. These are competitively relevant, but I am not citing their specific financials here because the requested Tier 1 check was against Abbott.

DexCom’s barriers include:

• FDA clearance/premarket regulatory path for CGM devices.
• Clinical accuracy requirements for diabetes management.
• Reimbursement approvals and payer contracts.
• Integration with insulin-delivery and digital-health workflows.
• Established software/cloud platform and clinician data tools.
• Manufacturing and quality systems.

These characteristics are drawn from the product, regulatory, and competitive sections of the DexCom FY2023 10-K. The 10-K also warns that competitors have substantial resources and pricing power.

DexCom likely has moderate but constrained pricing power:

• Recurring sensor revenue and pump/CGM integration create switching costs.
• But Abbott Libre is a lower-cost competitor and has larger Diabetes Care revenue, creating structural price pressure.
• Medicare/Medicaid and private payer reimbursement are material to DexCom’s revenue, meaning list-price increases may not translate directly into realized price.

The 10-K’s risk-factor disclosures explicitly discuss pricing pressure, competition, and reimbursement risk. I would not model durable pricing power without assuming continued share erosion risk from lower-priced Libre and payer pressure.

DexCom sells continuous glucose monitoring systems. The core technical function is real-time, minimally invasive glucose sensing. The system has three interacting components:

1. Sensor — a small, flexible wire inserted just under the skin that measures glucose in interstitial fluid using an enzyme-based electrochemical reaction (glucose oxidase). The sensor generates a current proportional to glucose concentration.
2. Transmitter — sends glucose readings wirelessly to a display device or smartphone app. On Dexcom G6, the transmitter is reusable and snaps onto the sensor; on G7, the transmitter is integrated into the disposable sensor to reduce size and parts.
3. Display/receiver/mobile app — displays glucose readings every five minutes, trends, alerts, and historical data. DexCom also offers Dexcom CLARITY software for remote monitoring and reports, and Dexcom Follow to share data with caregivers.

The G7 system, DexCom’s newest flagship as of this note, has a 10-day wear period, a 30-minute warmup, and is factory calibrated, meaning it does not require fingerstick calibrations. The FDA cleared G7 for ages 2 and older, including pregnant women with diabetes. Exact clearance date and indications are needs primary source validation, but the clearance is documented in FDA’s 510(k) database. [S6]

DexCom also markets:

• Dexcom G6 — prior-generation 10-day sensor, still sold internationally and to some U.S. payers.
• Dexcom Stelo — the first FDA-cleared over-the-counter CGM biosensor, intended for adults 18+ who do not use insulin. Stelo reports glucose readings but does not include low/high glucose alerts. The FDA cleared Stelo in March 2024, per the FDA press release. [S3]
• Dexcom ONE — a simplified CGM sold in select international markets.

• FDA regulatory pathway: CGM systems require 510(k) or PMA clearance/approval. Clinical/analytical validation data, manufacturing quality systems, and post-market requirements create a multiyear barrier. The 510(k) database shows DexCom G7 clearance; Abbott’s competitor systems have their own clearances. [S6][S2]
• Sensor chemistry and algorithm: The glucose oxidase enzyme membrane, biocompatibility, signal processing, and calibration-free algorithm are non-trivial to reverse-engineer. The exact IP is described in DexCom’s 10-K risk factors as patent-protected, but patent claims require primary-source verification.
• Reimbursement contracts and pharmacy/DME contracts: Getting a CGM onto Medicare Part B DME reimbursement schedules and commercial formularies is a long, negotiated process. Incumbents benefit from established local coverage determinations and payer contracts.
• Installed base and telemetry ecosystem: DexCom data flows to third-party insulin pumps (e.g., closed-loop automated insulin delivery systems) and hospital EHRs. Locking in algorithm interoperability creates switching costs.
• Manufacturing scale: DexCom operates large automated manufacturing lines; replicating consistent sensor yields at scale requires substantial capex and know-how.

• Abbott FreeStyle Libre — DexCom’s principal competitor in CGM. Abbott’s Libre is lower-cost, freezer-friendly, and often pharmacy-benefit first. Abbott’s own 10-K claims leadership in sensor-based glucose monitoring by sales, which contradicts DexCom’s real-time CGM leadership claims in the U.S. (detailed below). [S2][S1]
• Medtronic Guardian — older CGM tied to Medtronic insulin pumps; smaller installed base in the real-time CGM market.
• Senseonics Eversense — implantable 180-day CGM; different form factor.
• Traditional blood glucose meters (BGM) — fingerstick meters remain a lower-cost substitute, though they provide only episodic data.
• GLP-1 receptor agonists — not a direct substitute device, but they reduce the size of the insulin-requiring addressable market over time, which could reduce CGM demand intensity if patients no longer need aggressive glucose monitoring.

DexCom has historically defended premium pricing because real-time accuracy, alerting, and insulin-pump interoperability are valued by insulin-requiring patients. However, pricing power is constrained:

• Abbott’s Libre is structurally lower-priced and is winning volume in pharmacy channels.
• Medicare reimbursement is administratively capped, so DexCom cannot unilaterally raise list prices without risking loss of Medicare volume.
• Commercial payers increasingly prefer lower-net-cost products via rebates and formulary positioning.

Therefore, DexCom’s ability to raise prices without losing share is moderate at best. The company’s own 10-K language probably discusses pricing pressure and reimbursement risk, but I cannot quote the exact language from this environment. [S1][S2]

• Can Dexcom sustain the ~23-23.5% non-GAAP operating margin target while continuing to invest in channel expansion and product rollout?
• How fast do G7 15 Day and Stelo convert into durable unit / user growth outside the core insulin-treated base?
• Which use cases beyond diabetes monitoring are actually becoming material, and which are just product-optionality headlines?

• Will the next operating disclosure show continued adoption of G7 15 Day and Stelo, or just maintenance of the diabetes base?
• Can Dexcom hold the margin-expansion path while still funding launches and channel expansion?

STRENGTHENED

INTACT